Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus

A multicenter, randomized trial involving participants with diabetes and no evident cardiovascular disease at trial entry showed that aspirin led to a lower risk of serious vascular events than placebo but also caused a higher risk of major bleeding.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2018-10, Vol.379 (16), p.1529-1539
Hauptverfasser:	Bowman, Louise, Mafham, Marion, Wallendszus, Karl, Stevens, Will, Buck, Georgina, Barton, Jill, Murphy, Kevin, Aung, Theingi, Haynes, Richard, Cox, Jolyon, Murawska, Aleksandra, Young, Allen, Lay, Michael, Chen, Fang, Sammons, Emily, Waters, Emma, Adler, Amanda, Bodansky, Jonathan, Farmer, Andrew, McPherson, Roger, Neil, Andrew, Simpson, David, Peto, Richard, Baigent, Colin, Collins, Rory, Parish, Sarah, Armitage, Jane
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Aged, 80 and over Aspirin Aspirin - adverse effects Aspirin - therapeutic use Bleeding Cancer Cardiovascular disease Cardiovascular diseases Cardiovascular Diseases - epidemiology Cardiovascular Diseases - prevention & control Cerebral infarction Clinical trials Collaboration Data analysis Diabetes Diabetes Complications - epidemiology Diabetes Complications - prevention & control Diabetes mellitus Diabetes Mellitus - drug therapy Disease prevention Fatty acids Female Follow-Up Studies Gastrointestinal cancer Gastrointestinal tract Hemorrhage Hemorrhage - chemically induced Hemorrhage - epidemiology Humans Information sharing Ischemia Male Medical research Middle Aged Myocardial infarction Platelet Aggregation Inhibitors - adverse effects Platelet Aggregation Inhibitors - therapeutic use Poisson Distribution Population Primary Prevention Questionnaires Risk Factors Transient ischemic attack Writing
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	A multicenter, randomized trial involving participants with diabetes and no evident cardiovascular disease at trial entry showed that aspirin led to a lower risk of serious vascular events than placebo but also caused a higher risk of major bleeding.
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMoa1804988